231 related articles for article (PubMed ID: 10027726)
1. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
3. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
4. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
7. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
[TBL] [Abstract][Full Text] [Related]
9. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
10. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
[TBL] [Abstract][Full Text] [Related]
11. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
14. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
Kovarova L; Buresova I; Buchler T; Suska R; Pour L; Zahradova L; Penka M; Hajek R
Neoplasma; 2009; 56(6):526-32. PubMed ID: 19728762
[TBL] [Abstract][Full Text] [Related]
15. Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
Klimienė I; Radzevičius M; Matuzevičienė R; Sinkevič-Belliot K; Kučinskienė ZA; Pečeliūnas V
Int J Lab Hematol; 2021 Jun; 43(3):403-408. PubMed ID: 33185981
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
[TBL] [Abstract][Full Text] [Related]
17. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
Kraj M; Sokołowska U; Kopeć-Szlezak J; Pogłód R; Kruk B; Woźniak J; Szpila T
Leuk Lymphoma; 2008 Feb; 49(2):298-305. PubMed ID: 18231917
[TBL] [Abstract][Full Text] [Related]
20. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
